EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.

European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado

doi:10.1016/j.jhep.2015.04.006

EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.

European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado

MeSH — NLM indexing Carcinoma, Hepatocellular / diagnosis Diagnostic Techniques, Digestive System / standards Europe Humans Liver Neoplasms / diagnosis Prognosis Severity of Illness Index

Actions du personnel

Télécharger le PDF

Les fichiers sont réservés à un usage autorisé dans les canaux partenaires BioPredictive.

Key publication Fibrotest Actitest Guideline Independent Group Switzerland

Auteurs (2)

Citation

European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-64. doi:10.1016/j.jhep.2015.04.006.

Identifiants

DOI: 10.1016/j.jhep.2015.04.006
PMID: 25911335

Tests

Maladies du foie

Atteintes hépatiques

Comparaisons

Thèmes

Région

Panier

Votre panier est vide.

Parcourez les publications et utilisez Ajouter au panier sur n'importe quelle page de détail pour constituer une archive ZIP à envoyer aux clients.

Parcourir les publications

EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.

Sur le même sujet

An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

Noninvasive Assessment of Liver Fibrosis.

Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.

Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).